Functional Capacity Evaluation | NYU Langone Health
NYU Langone Occupational and Industrial Orthopedic Center offers evaluations to determine a person’s ability to perform physical work.
Gamma Knife Radiosurgery | NYU Langone Health
Physicians at NYU Langone’s Center for Advanced Radiosurgery are experts in Gamma Knife treatment for neurological conditions.
Gamma Knife Radiosurgery for Glioma & Astrocytoma | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use noninvasive Gamma Knife® radiosurgery to manage gliomas and astrocytomas.
Gamma Knife Radiosurgery for Metastatic Brain Tumors | NYU Langone Health
NYU Langone physicians may use Gamma Knife radiosurgery to manage metastatic brain tumors that can’t be surgically removed.
Ganglion Cysts | NYU Langone Health
NYU Langone specialists offer several treatment options for ganglion cysts, noncancerous lumps that develop on the wrist or hand.
Gastroenterology Research & Clinical Trials | NYU Langone Health
NYU Langone Long Island Clinical Research Associates offers opportunities to participate in clinical trials and research studies.
Gastroesophageal Reflux Disease | NYU Langone Health
NYU Langone specialists care for patients with gastroesophageal reflux disease, or GERD, using advanced diagnostic technologies and treatments.
Gastrointestinal tract colonization and Staphylococcus aureus associated skin diseases
The purpose of this study is to understand the relationship between skin diseases and a bacterial species called Staphylococcus aureus. This bacterial species is found on the skin and the presence of Staphylococcus aureus has been associated with worse outcomes of skin diseases such as atopic dermatitis and furunculosis. Little is known about whether presence of Staphylococcus aureus in the gut affects diseases on the skin. This study aims to understand whether Staphylococcus aureus in the gut affects skin disease. Currently, this study focuses on infants and children who have higher rates of Staphylococcus aureus gastrointestinal colonization.
Gaucher Disease Outcome Survey (GOS)
Gaucher disease is one of several rare lysosomal storage disorders, affects 10,000-30,000 patients worldwide, and is classified into three clinical subtypes. Type 1 Gaucher disease is the most common type. It commonly affects the liver, spleen, bone marrow and rarely the kidneys. The brain is not affected. Type II disease begins within 6 months of birth and affects about half as many individuals as type 1 disease. In addition to involvement of the liver, spleen and bone marrow, the brain is affected causing brain damage and usually death by the age of 2 years. Type III Gaucher disease can occur at any time in childhood or adulthood. It is characterized by chronic and slowly progressive symptoms involving the liver, spleen and bone marrow and the nervous system. Patients with this type of disease usually live into adulthood. The objective of the study is to learn the natural history of the disease as well as the disease response to various treatments, to monitor the safety and effectiveness of treatment with velaglucerase alfa enzyme (VPRIV®) which is approved for Type I Gaucher disease, and other treatments, to learn more about the quality of life of patients with Gaucher disease and to provide information to the regulators who require ongoing information on the safety and effectiveness of VPRIV®.
GBM Agile Trial
The purpose of the research study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatments improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. If you choose to participate in the study, you will be randomized like the flipping of a coin or the rolling of dice, to determine which treatment you will receive.